Innovation in Pediatric Drugs Act of 2025

This bill gives the FDA more power to require studies on how certain rare disease drugs work in children. Right now, drugs for rare diseases usually don't have to be tested in kids, but this bill would change that if the FDA decides the drug could improve treatment for children or if more options are needed. The bill also lets the FDA take action against drug companies that don't follow through on required children's studies and sets aside funding through the National Institutes of Health for research focused on children's health needs. A government report would also be required to look at how these changes affect the development of rare disease drugs and the availability of information about how these drugs work in kids.

Your Vote